These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34925435)

  • 21. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
    Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
    Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
    Zhu Q; Wang J; Zhang W; Zhu W; Wu Z; Chen Y; Chen M; Zheng L; Tang J; Zhang S; Wang D; Wang X; Chen G
    Front Genet; 2022; 13():878618. PubMed ID: 35646048
    [No Abstract]   [Full Text] [Related]  

  • 23. Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.
    Laurent C; Nicolae A; Laurent C; Le Bras F; Haioun C; Fataccioli V; Amara N; Adélaïde J; Guille A; Schiano JM; Tesson B; Traverse-Glehen A; Chenard MP; Mescam L; Moreau A; Chassagne-Clement C; Somja J; Escudié F; André M; Martin N; Lacroix L; Lemonnier F; Hamy AS; Reyal F; Bannier M; Oberic L; Prade N; Frénois FX; Beldi-Ferchiou A; Delfau-Larue MH; Bouabdallah R; Birnbaum D; Brousset P; Xerri L; Gaulard P
    Blood; 2020 Jan; 135(5):360-370. PubMed ID: 31774495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.
    You H; Xu-Monette ZY; Wei L; Nunns H; Nagy ML; Bhagat G; Fang X; Zhu F; Visco C; Tzankov A; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Van Krieken JH; Piris MA; Winter JN; Li Y; Au Q; Xu B; Albitar M; Young KH
    Oncoimmunology; 2021; 10(1):1928365. PubMed ID: 34350060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific Mutation Predict Relapse/Refractory Diffuse Large B-Cell Lymphoma.
    Wang J; Tian L; Zhang W; Tang S; Zhao W; Guo Y; Wu C; Lin Y; Ke X; Jing H
    J Blood Med; 2024; 15():407-419. PubMed ID: 39279878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational profile of primary breast diffuse large B-cell lymphoma.
    Franco F; González-Rincón J; Lavernia J; García JF; Martín P; Bellas C; Piris MA; Pedrosa L; Miramón J; Gómez-Codina J; Rodríguez-Abreu D; Machado I; Illueca C; Alfaro J; Provencio M; Sánchez-Beato M
    Oncotarget; 2017 Nov; 8(61):102888-102897. PubMed ID: 29262531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression.
    Ma J; Yan Z; Zhang J; Zhou W; Yao Z; Wang H; Chu J; Yao S; Zhao S; Zhang P; Xu Y; Xia Q; Ma J; Wei B; Yang S; Liu K; Guo Y; Liu Y
    Biomark Res; 2020; 8():33. PubMed ID: 32864130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of SOCS1 mutations in diffuse large B-cell lymphoma.
    Mellert K; Martin M; Lennerz JK; Lüdeke M; Staiger AM; Kreuz M; Löffler M; Schmitz N; Trümper L; Feller AC; Hartmann S; Hansmann ML; Klapper W; Stein H; Rosenwald A; Ott G; Ziepert M; Möller P
    Br J Haematol; 2019 Dec; 187(5):627-637. PubMed ID: 31407320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma.
    Barasch NJK; Liu YC; Ho J; Bailey N; Aggarwal N; Cook JR; Swerdlow SH
    Hum Pathol; 2020 Dec; 106():93-105. PubMed ID: 33045225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma.
    Wang HY; Sokol ES; Goodman AM; Feldman AL; Mulroney CM
    Front Oncol; 2021; 11():620435. PubMed ID: 33777766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next-Generation Integrated Sequencing Identifies Poor Prognostic Factors in Patients with MYD88-Mutated Chronic Lymphocytic Leukemia in Taiwan.
    Huang YJ; Lim JQ; Hsu JS; Kuo MC; Wang PN; Kao HW; Wu JH; Chen CC; Tsai SF; Ong CK; Shih LY
    Pathobiology; 2024 Oct; ():1-13. PubMed ID: 39357512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.
    Chapman JR; Bouska AC; Zhang W; Alderuccio JP; Lossos IS; Rimsza LM; Maguire A; Yi S; Chan WC; Vega F; Song JY
    Br J Haematol; 2021 Sep; 194(5):870-878. PubMed ID: 34272731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.
    Dobashi A
    J Clin Exp Hematop; 2016; 56(2):71-78. PubMed ID: 27980305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation.
    Santos Gda C; Saieg MA; Ko HM; Geddie WR; Boerner SL; Craddock KJ; Crump M; Bailey D
    Cancer Cytopathol; 2015 Jul; 123(7):413-20. PubMed ID: 25807917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
    Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
    EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Dobashi A; Togashi Y; Tanaka N; Yokoyama M; Tsuyama N; Baba S; Mori S; Hatake K; Yamaguchi T; Noda T; Takeuchi K
    Oncotarget; 2018 Apr; 9(28):19555-19568. PubMed ID: 29731965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.
    Pedrosa L; Fernández-Miranda I; Pérez-Callejo D; Quero C; Rodríguez M; Martín-Acosta P; Gómez S; González-Rincón J; Santos A; Tarin C; García JF; García-Arroyo FR; Rueda A; Camacho FI; García-Cosío M; Heredero A; Llanos M; Mollejo M; Piris-Villaespesa M; Gómez-Codina J; Yanguas-Casás N; Sánchez A; Piris MA; Provencio M; Sánchez-Beato M
    Sci Rep; 2021 Jan; 11(1):1886. PubMed ID: 33479306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Characterization of Primary Mediastinal Large B-Cell Lymphomas.
    Donzel M; Pesce F; Trecourt A; Groussel R; Bachy E; Ghesquières H; Fontaine J; Benzerdjeb N; Mauduit C; Traverse-Glehen A
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.
    Mottok A; Hung SS; Chavez EA; Woolcock B; Telenius A; Chong LC; Meissner B; Nakamura H; Rushton C; Viganò E; Sarkozy C; Gascoyne RD; Connors JM; Ben-Neriah S; Mungall A; Marra MA; Siebert R; Scott DW; Savage KJ; Steidl C
    Blood; 2019 Sep; 134(10):802-813. PubMed ID: 31292115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of DLBCL with a PMBL gene expression signature.
    Duns G; Viganò E; Ennishi D; Sarkozy C; Hung SS; Chavez E; Takata K; Rushton C; Jiang A; Ben-Neriah S; Woolcock BW; Slack GW; Hsi ED; Craig JW; Hilton LK; Shah SP; Farinha P; Mottok A; Gascoyne RD; Morin RD; Savage KJ; Scott DW; Steidl C
    Blood; 2021 Jul; 138(2):136-148. PubMed ID: 33684939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.